Almac Adds Simple Solutions to Bridge the Gap Between Clinical and Commercial Packaging
Addressing client demand to ease the transition between clinical and commercial launch for blister products...
Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac, provider in clinical and commercial contract packaging to the global Pharmaceutical and Biotech industries, has added new blistering technology at their US commercial packaging facility in Audubon, PA
The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials. This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.
David Moore, Director of Operations at the Audubon facility explains “Almac are offering seamless services from clinical supply, packaging development / design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services.”
The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial /ampoule labelling available at Almac.
For more information on Almac’s US packaging capabilities, please contact
[email protected]
Almac will be exhibiting at Pharma Packaging & Labeling Philadelphia 26 – 27 Feb 2014 and Interphex New York 18 – 20 March 2014.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
